The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicinand mitoxantrone-induced cardiotoxicity

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 4, 2001, Pages 297-304

  Itokawa, Hideji ^a   Takeya, Koichi ^a   Hitotsuyanagi, Yukio ^a   Morita, HiroShi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Cardiac troponin T; Cardiotoxicity; Dexrazoxane; Doxorubicin; Mitoxantrone

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; CHELATING AGENT; DEFEROXAMINE; DOXORUBICIN; EDETIC ACID; IRON COMPLEX; MITOXANTRONE; PENTETIC ACID; RAZOXANE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL VACUOLE; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; ESSENTIAL HYPERTENSION; HEART INJURY; HEART PROTECTION; MALE; MICROSCOPY; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RATING SCALE; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; DOXORUBICIN; HEART; INFUSIONS, INTRAVENOUS; MALE; MITOXANTRONE; MYOCARDIUM; RATS; RATS, INBRED SHR; RAZOXANE; TROPONIN T;

EID: 0034846427     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100348     Document Type: Article

References (42)

1. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model
2. Rationale for the use of mitoxantrone in the older patient: Cardiac toxicity
3. Role of endomyocardial biopsy in diagnosis and treatment of heart disease
4. Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage
5. Cardioprotection by ICRF 187 against high dose anthracycline toxicity in children with malignant disease
6. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes
7. Pathologic anatomy of animal models of anthracycline-induced cardiotoxicity
8. Role of myocardial biopsy in the diagnosis of anthracycline toxicity
9. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy
10. The role of free radical formation in the cardiotoxicity of anthracycline
11. Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen
12. The interaction of the cardioprotective agent ICRF-187 [+]-1,2-bis(3,5-dioxopiperazinyl-l-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin
13. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: Comparison with doxorubicin. I. Clinical observations
14. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer
15. Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity
16. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats
17. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats
18. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex
19. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity
20. Comparison of the chronic toxicity of piroxantrone, losoxantrone and doxorubicin in spontaneously hypertensive rats
21. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin
22. Enzyme linked immunoassay of cardiac troponin T for the detection of acute myocardial infarction in patients
23. Diagnostic efficiency of troponin T measurements in acute myocardial infarction
24. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and non-reperfused myocardial infarction
25. Development and in vitro characterization of a new immunoassay of cardiac troponin T
26. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy
27. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury
28. Progress in myocardial damage detection: New biochemical markers for clinicians
29. Cardiac troponin T in diagnosis of acute myocardial infarction
30. Improved troponin T ELISA specific for cardiac troponin T isoform: Assay development and analytical and clinical validation
31. Myocardial damage in doxorubicin-treated children: A study of serum cardiac troponin T
32. Mitoxantrone: An overview of safety and toxicity
33. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim
34. Cardioprotective effects of ACE-inhibitor (Cilazapril) on adriamycin cardiotoxicity in spontaneously hypertensive rats
35. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells
36. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: Comparison with doxorubicin. II. Histologic and ultrastructural pathology
37. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
38. The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin
39. Cardiac evaluation of mitoxantrone
40. Mitoxantrone: Its development and role in clinical practice
41. Coincident acute myelogenous leukemia and ischemic heart disease: Use of the cardioprotectant dexrazoxane during induction chemotherapy